The Akkermansia Company - Belgium

The Akkermansia Company™ is proud to announce that their New Generation strain  Akkermansia muciniphila MucT™ has now been approved in Australia for use in therapeutic goods. It’s the only Akkermansia muciniphila that has European Food Safety approval (EFSA), the only Akkermansia that has clinical studies with humans and with its pasteurisation process demonstrates an unparalleled safety profile. If this is something of interest and you have an opportunity to launch in the Australian market please message us direct or send an email to info@theakkermansiacompany.com

Headlining this week's CHC.NewDirections, a CHC.Newsflash Extra: The Akkermansia Company - Belgium (previously known as A-mansia Biotech) has launched into the US consumer market with its “new-generation postbiotic” Akkermansia muciniphila supplements. The first supplement available – Healthy Weight, in Europe since 2021 – is positioned to strengthen the gut barrier, promote weight management and support both longevity and vitality. Each serving (recommended use: 1 tablet daily) contains pasteurised A. muciniphila MucT (30bn TFUs – total fluorescent units), green tea extract epigallocatechin gallate (EGCG; 100mg), green tea leaf extract (200mg), chromium (200mcg), vitamin D (5mcg) and vitamin B2 (0.21mg). A 30-day supply costs US$59.99 on Amazon. Link In 2004, The company’s co-founder Professor Willem M de Vos and his team at Belgium’s Wageningen University & Research were the first to discover and decode A. muciniphila. In fact, the strain was named in honour of Dr Anton Akkermans, a microbial ecologist working in their lab. The probiotic strain came to our attention in 2015, when we reported a clinical study that suggested the probiotic may hold the key to better metabolic health in overweight and obese people . In 2018, the researchers created A-Mansia as a spin-off from Wageningen University and secured Series A funding, with dreams of commercialising their probiotic supplement. The team went on to develop pasteurised A. muciniphila MucT, which gained approval as a Novel Food in Europe in 2021. Akkermansia is now a well-recognised and well-studied probiotic strain and features in several commercial supplements. The team behind The Akkermansia Company, as it is now known, were steadfast in their dedication to their probiotic and the benefits it could bring. We’re delighted the company has spread its wings to the USA and wish them all the best in their endeavours. To read more of my thoughts on this and other key CHC headlines and developments, trial our combined news service by contacting Melissa #consumerhealthcare #CHC #CHCNewsflash #CHCNewDirections #Akkermansia #muciniphila #probiotic #Wageningen #weightmanagement #guthealth

Headlining this week's CHC.NewDirections, a CHC.Newsflash Extra: The Akkermansia Company - Belgium (previously known as A-mansia Biotech) has launched into the US consumer market with its “new-generation postbiotic” Akkermansia muciniphila supplements. The first supplement available – Healthy Weight, in Europe since 2021 – is positioned to strengthen the gut barrier, promote weight management and support both longevity and vitality. Each serving (recommended use: 1 tablet daily) contains pasteurised A. muciniphila MucT (30bn TFUs – total fluorescent units), green tea extract epigallocatechin gallate (EGCG; 100mg), green tea leaf extract (200mg), chromium (200mcg), vitamin D (5mcg) and vitamin B2 (0.21mg). A 30-day supply costs US$59.99 on Amazon. Link In 2004, The company’s co-founder Professor Willem M de Vos and his team at Belgium’s Wageningen University & Research were the first to discover and decode A. muciniphila. In fact, the strain was named in honour of Dr Anton Akkermans, a microbial ecologist working in their lab. The probiotic strain came to our attention in 2015, when we reported a clinical study that suggested the probiotic may hold the key to better metabolic health in overweight and obese people . In 2018, the researchers created A-Mansia as a spin-off from Wageningen University and secured Series A funding, with dreams of commercialising their probiotic supplement. The team went on to develop pasteurised A. muciniphila MucT, which gained approval as a Novel Food in Europe in 2021. Akkermansia is now a well-recognised and well-studied probiotic strain and features in several commercial supplements. The team behind The Akkermansia Company, as it is now known, were steadfast in their dedication to their probiotic and the benefits it could bring. We’re delighted the company has spread its wings to the USA and wish them all the best in their endeavours. To read more of my thoughts on this and other key CHC headlines and developments, trial our combined news service by contacting Melissa #consumerhealthcare #CHC #CHCNewsflash #CHCNewDirections #Akkermansia #muciniphila #probiotic #Wageningen #weightmanagement #guthealth

Curious about the latest advancement in gut bacteria? Watch our video to learn more about Akkermansia, a next-generation strain discovered, developed, and patented by the visionary founders of The Akkermansia Company™. 🦠 Nestled in your gut, its unique properties make it a key player in maintaining a healthy microbiome balance. Plus, its presence (or absence) might offer vital insights into potential disease markers. As the wise words of Hippocrates remind us, "All disease begins in the gut." Stay informed about the latest breakthrough in gut health and unlock the secrets of a healthier you. #akkermansia #guthealth #TheAkkermansiaCompany

We are thrilled to announce that our next-generation gut bacteria supplements are now available in Ireland for Health Care Professionals through our stockists at Clean Living (https://cleanliving.ie/) and Pure and Natural (https://pureandnatural.ie/). Our supplements are formulated with 30 billion patented, pasteurised Akkermansia strain, backed by 17 years of extensive scientific research. Clinically proven, these breakthrough supplements empower individuals on their journey to taking control of their health. Join our mission to improve metabolic health. Learn more at https://lnkd.in/efvtBidp #GutHealth #Akkermansia #HealthcareInnovation #TheAkkermansiaCompany #Irelandhealthcare #HCP

The Akkermansia Company™ found to be the “First to file” patent application to treat obesity through oral use of the probiotic Akkermansia. Decision Rendered by Patent Trial and Appeal Board of USPTO As Company Launches New Probiotic Supplement in U.S. Health Care Channel   The Akkermansia Company™, a pioneer in developing “next generation” probiotics and postbiotics, has announced that the Patent Trial and Appeal Board (Board) of the United States Patent and Trademark Office (USPTO) has issued a decision in a patent interference involving the probiotic Akkermansia.   In that decision, the Board found that the inventors of applications licensed to The Akkermansia Company™ — Cani et al. — were the first to file a patent application related to treating a metabolic disorder such as obesity with the oral administration of Akkermansia, before Kaplan et al., the inventors of applications licensed to Pendulum Therapeutics, Inc. “The Patent Office has, in effect, stated that the Cani inventors were the first to make the invention, something we were certain of before asking Cani to request the declaration of an interference,” said Michael Oredsson, Chief Executive Officer of The Akkermansia Company™. “While the upcoming second stage of the interference will allow Kaplan to present its priority case, we are confident that the decision that the Cani inventors were first will be confirmed in the final decision.” https://lnkd.in/egigQFMC

Exciting news from The Akkermansia Company! 🚀 We're thrilled to announce that the European Investment Bank (EIB) has invested €20 million in venture debt financing to support our mission in advancing microbiome health. This funding will be pivotal in accelerating our R&D and commercial initiatives, specifically focusing on the incredible potential of Akkermansia muciniphila bacteria. Scientific studies have highlighted the critical role this bacteria plays in strengthening gut barrier functions, and with the EIB's support through the InvestEU programme, we are poised to make significant strides in this field. As CEO Michael Oredsson stated, "We will use the EIB venture debt financing to accelerate our commercial and R&D efforts, amongst others by conducting additional clinical trials aimed at demonstrating the health benefits of pasteurised Akkermansia muciniphila in several areas." Want to learn more? Read the full article here: https://lnkd.in/gk8TJmbg We're grateful for this opportunity and committed to leveraging these resources to propel our innovative work forward. Here's to the future of gut health and well-being! 🦠 #TheAkkermansiaCompany #MicrobiomeInnovation #InvestEU #GutHealth #microbiomehealth